Review Article
Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Table 2
DUET trials: summary efficacy and safety results by treatment arm, to Week 48.
| | | Etravirine + BR | Placebo + BR |
| | HIV RNA <50 c/mL, ITT | 363 (61%) | 240 (40%) | | Any grade 3 or 4 adverse event | 199 (33%) | 211 (35%) | | Adverse events leading to discontinuation | 43 (7%) | 34 (6%) | | Grades 1–4 clinical adverse events of interest | | | | Nervous system | 103 (17%) | 119 (20%) | | Psychiatric | 100 (17%) | 118 (20%) | | Rash | 60 (10%) | 21 (4%) | | Grades 3-4 laboratory abnormalities | | | | Elevated ALT | 22 (4%) | 12 (2%) | | Elevated AST | 19 (3%) | 12 (2%) | | Elevated total cholesterol | 48 (8%) | 32 (5%) | | Elevated LDL | 42 (7%) | 39 (7%) | | Elevated triglycerides | 55 (10%) | 35 (6%) |
|
|
BR: background regimen of optimized nucleoside analogues plus optional enfuvirtide.
, comparison between treatment arms at Week 48.
|
